Loading data for PRME — first visit, this takes a few seconds.
Prime Medicine, Inc. (PRME)
NasdaqGM: PRME
· 实时价格 · USD
3.70
-0.01 (-0.27%)
收盘价： Sep 04, 2026, 3:59 PM
3.72
+0.53%
盘后: 7:48 PM
股价、关键数字和最新消息，都在这一页。
Prime Medicine, Inc.（PRME）股价、分析与数据
-0.27% (1D)
| 买价 | 2.24 |
| 市值 | 671M |
| 营收（TTM） | 4.07M |
| 净利润（TTM） | -188M |
| 2.35 | |
| -1.05 | |
| n/a | |
| -4.19 | |
| 市净率（TTM） | 16.44 |
| 市销率（TTM） | 164.77 |
| 财报日期 | Nov 6, 2026 |
| 卖价 | 3.71 |
| 成交量 | 1,619,295 |
| 20日均量 | 3,209,539 |
| 开盘价 | 3.80 |
| 前收盘价 | 3.71 |
| 日内区间 | 3.65 - 3.86 |
| 52周区间 | 2.67 - 6.94 |
| 分析师 | n/a |
| 目标价 | n/a |
| 分红 | n/a |
| 除息日 | n/a |
关于 PRME
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting i...
公司完整简介财报意外
Prime Medicine 已于 Aug 6, 2026 发布季度财报：
- 营收为 $1.15M 低于预期 $0, ， 3.50% 同比增长.
- 每股收益为 -0.24 超出预期 0.02, ， 41.46% 同比增长.
第 1 页，共 2 页